What’s the deal? EuBiologics, a Korean vaccine developer, said Wednesday it has invested $10 million (about 13.8 billion won) in its subsidiary EuPOP Life Sciences, raising its equity stake to 80%. The company will acquire 8,750 newly issued shares through a third-party allotment, bringing its holdings to 15,000 shares.
What’s the endgame? EuPOP Life Sciences is a joint venture between EuBiologics and US-based Pop Biotechnologies. It develops vaccines against RSV, shingles, and Alzheimer’s disease by combining EuBiologics’ EuIMT immune-enhancing technology with Pop Biotechnologies’ SNAP nanoparticle-based antigen delivery platform.
Where the money goes: EuPOP will use the funds to accelerate clinical development across its pipeline. The company recently filed an investigational new drug (IND) application for a phase 1 trial of its Alzheimer’s therapeutic vaccine and is pursuing a follow-up trial for its shingles vaccine.
Why now? The investment supports continued research and development while strengthening EuBiologics’ control over the subsidiary. Pop Biotechnologies, which has worked with the US National Institutes of Health, recently secured up to $9.7 million from the Coalition for Epidemic Preparedness Innovations to advance its SNAP platform.
What’s the endgame, longer term? EuBiologics plans to develop EuPOP into a global hub for clinical and business development of premium vaccines. It intends to pursue licensing deals, co-development partnerships, and fundraising with global pharmaceutical companies, and eventually a Nasdaq listing for EuPOP.
“This investment is intended to enhance the global competitiveness of the premium vaccines being developed through EuPOP Life Sciences and accelerate their clinical development and commercialization,” a EuBiologics official said.
The signal: By deepening its control over a US-based joint venture, EuBiologics is positioning a Korean-American vaccine partnership for global markets and eventual public listing — a route that pairs domestic technology with US clinical and commercial reach.
Read more: koreabiomed.com
Image credit: foteih
Leave a comment